DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Robert C, Ribas A, Wolchok JD et al.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet 2014;
384: 1109-1117
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.